About this trial
This prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to characterize molecular spectral patterns and assess their association with the current standard diagnosis of lung cancer.
The study plans to enroll 2,000 participants with pathologically confirmed lung cancer and 1,000 participants without lung cancer. Diagnostic performance will be evaluated using measures including sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve analysis. Exploratory analyses will assess performance according to lung cancer histological subtype, disease stage, and longitudinal clinical status.
Eligibility criteria
Qualifiers
Age 18 years or older.
Underwent low-dose computed tomography or chest computed tomography within the previous 2 years.
Pathologically confirmed lung cancer.
Histological diagnosis of adenocarcinoma, squamous cell carcinoma, or small cell lung cancer, with TNM stage determined by a thoracic physician.
Disqualifiers
1. Younger than 18 years of age. 2. Unable to understand the study information or provide written informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Taichung Veterans General Hospital
Lead sponsor
Far Eastern Memorial Hospital
Collaborator
Taoyuan General Hospital, Ministry of Health and Welfare
Collaborator